{"id":"imp4927","safety":{"commonSideEffects":[{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CSF1R inhibition decreases the recruitment and survival of tumor-associated macrophages (TAMs), which are immunosuppressive cells that promote tumor growth and metastasis. By depleting or reprogramming these macrophages, IMP4927 aims to enhance anti-tumor immunity and improve the efficacy of checkpoint inhibitors or other immunotherapies.","oneSentence":"IMP4927 is a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) that reduces macrophage infiltration and activation in the tumor microenvironment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:48.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT04169997","phase":"PHASE3","title":"A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Impact Therapeutics, Inc.","startDate":"2019-12-24","conditions":"Ovarian Cancer","enrollment":404}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IMP4927","genericName":"IMP4927","companyName":"Impact Therapeutics, Inc.","companyId":"impact-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IMP4927 is a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) that reduces macrophage infiltration and activation in the tumor microenvironment. Used for Advanced solid tumors (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}